Moderna Inc. faced a significant downturn in its stock price as investor concerns mount ahead of its upcoming earnings report.
Moderna Inc. (NASDAQ:MRNA) experienced a sharp decline yesterday, closing down 5.00% at CA$213.74. This drop comes as the company prepares to report its third-quarter financial results, raising questions about its future performance amidst a challenging market environment.
Advertisement
Moderna Inc
MRNA.US
MRNA.US
Moderna Inc
WealthAwesomeMarket cap
$85.33B
52W high
$227.46
52W low
$22.28
1W change
+5.18%
Beta
1.09
Analyst Price Targets
Based on 23 analysts covering MRNA · as of Oct 12, 2026
Wall Street analysts forecast MRNA stock price to fall 42.6% over the next 12 months.
Consensus
Hold3.17 / 5.00
Avg. Target
C$122.67
-42.6% Upside
Previously C$121.00 on Oct 8, 2026
Current Price
C$213.74
Last close
Analyst Breakdown (23 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
81.8%
Annualized
90-Day Vol
195.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$255.53
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$226.85 | C$171.08 – C$300.79 |
| 60 trading days | C$240.76 | C$161.55 – C$358.81 |
| 90 trading days | C$255.53 | C$156.75 – C$416.55 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should brace for potential volatility as Moderna approaches its earnings report, with analysts predicting a significant year-over-year decline in earnings and revenue.
5.00% Drop in Stock Price
Moderna's stock fell 5.00% yesterday, underperforming the broader market, which saw only a minor decline.
Bull case
If Moderna surprises the market with better-than-expected earnings or positive updates on its drug pipeline, it could regain investor confidence and see a rebound in its stock price.
Bear case
On the other hand, if the earnings report shows deeper losses or disappointing revenue figures, it could further erode investor trust and lead to more sell-offs.
Advertisement
Market Performance Overview
Yesterday, Moderna's stock closed at CA$213.74, reflecting a 5.00% decrease. This decline was particularly notable as it significantly outpaced the S&P 500's minimal loss of 0.06% for the same day. The biotechnology sector has been under pressure, and Moderna's performance raises concerns about its ability to sustain its recent gains.
Earnings Expectations and Investor Sentiment
As Moderna prepares to report its third-quarter results on November 6, 2026, analysts are projecting a substantial decline in earnings per share to -$1.37, a 168.63% drop from the previous year. Revenue is also expected to fall by 12.52% year-over-year, leading to increased scrutiny from investors regarding the company's future prospects.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
